Quotient Therapeutics

Founded in 2022, the Flagship spin-out is the first to study the human body’s genetic variation and the evolution of its trillion-strong cells.

Quotient’s proprietary single molecule, genome sequencing technology platform focuses on somatic genomics (i.e., cellular-level genetic variation), to facilitate the identification of new links between genes and disease and inform drug discovery to prevent, cure or reverse disease.

Co-founded by world-class academics, including former Wellcome Sanger Institute director Sir Mike Stratton, Quotient operates from its research bases in Cambridge UK and Cambridge US.

Career opportunities at Quotient Therapeutics